EFFICACY
Reduction in serum ferritin
In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox® treatment offered a decrease in serum ferritin level in patients whose prior chelation therapy was inadequate.
Decrease in cardiac iron load
In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox treatment offered a decrease in cardiac iron load in patients whose prior chelation therapy was inadequate.
Reduction in liver iron concentration (LIC)
In pooled clinical trials that led to accelerated FDA approval, 1 year of Ferriprox treatment offered a decrease in LIC in patients whose prior chelation therapy was inadequate.
